Clinical characteristics and prognosis of childhood acute lymphoblastic leukemia with CD123 expression

ZHU Ke-Fu; LI Hai-Jin; QIAO Chuan-Fu; WANG Liu-Fang; WU Pei-Jing; CHEN Ying; TIAN Xin

doi:10.7499/j.issn.1008-8830.2312152

PDF(576 KB)

Chinese Journal of Contemporary Pediatrics ›› 2024, Vol. 26 ›› Issue (7) : 708-715. DOI: 10.7499/j.issn.1008-8830.2312152

CLINICAL RESEARCH

Clinical characteristics and prognosis of childhood acute lymphoblastic leukemia with CD123 expression

ZHU Ke-Fu, LI Hai-Jin, QIAO Chuan-Fu, WANG Liu-Fang, WU Pei-Jing, CHEN Ying, TIAN Xin

Author information +

History +

Abstract

Objective To investigate the expression of CD123 in children with acute lymphoblastic leukemia (ALL) and its effect on the clinical characteristics and prognosis of children with B-lineage acute lymphoblastic leukemia (B-ALL). Methods A retrospective analysis was conducted on the clinical data of 251 children with ALL who were admitted to the Department of Hematology and Oncology, Children's Hospital of Kunming Medical University, from December 2019 to June 2022. According to the expression of CD123 at initial diagnosis, the children were divided into CD123⁺ group and CD123^- group, and the two groups were compared in terms of clinical characteristics and treatment outcome. The factors influencing the prognosis were analyzed. Results Among the 251 children with ALL, there were 146 children (58.2%) in the CD123⁺ group. The B-ALL group had a significantly higher positive expression rate of CD123 than the acute T lymphocyte leukemia group (P<0.05). Compared with the CD123^- group, the CD123⁺ group had significantly lower peripheral blood leukocyte count and percentage of juvenile cells and a significantly higher proportion of children with high hyperdiploid karyotype or an age of 1-10 years, with a relatively low proportion of children with E2A-PBX1 fusion gene (P<0.05). The multivariate Cox proportional-hazards regression model analysis showed that compared with the >10 years group, the 1-10 years group had a significantly higher overall survival rate (P<0.05), and compared with the high risk group, the moderate risk group had a significantly higher event-free survival rate in children with B-ALL (P<0.05). Conclusions CD123 is widely expressed in children with B-ALL, and positive expression of CD123 might be an indicator for good prognosis in children with B-ALL, which is of great significance for evaluating the efficacy of remission induction therapy and survival prognosis of children with B-ALL.

Key words

Acute lymphoblastic leukemia / Leukemia stem cell / CD123 / Prognosis / Child

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

ZHU Ke-Fu, LI Hai-Jin, QIAO Chuan-Fu, WANG Liu-Fang, WU Pei-Jing, CHEN Ying, TIAN Xin. Clinical characteristics and prognosis of childhood acute lymphoblastic leukemia with CD123 expression[J]. Chinese Journal of Contemporary Pediatrics. 2024, 26(7): 708-715 https://doi.org/10.7499/j.issn.1008-8830.2312152

References

1 Inaba H, Pui CH. Advances in the diagnosis and treatment of pediatric acute lymphoblastic leukemia[J]. J Clin Med, 2021, 10(9): 1926. PMID: 33946897. PMCID: PMC8124693. DOI: 10.3390/jcm10091926.
2 张蕾, 岳梅, 玄立田, 等. 儿童急性T淋巴细胞白血病的临床特征及预后分析[J]. 中国小儿血液与肿瘤杂志, 2023, 28(1): 4-8. DOI: 10.3969/j.issn.1673-5323.2023.01.002.
3 邹尧, 陈晓娟, 刘晓明, 等. 单中心应用CCLG-ALL2008方案治疗940例儿童急性淋巴细胞白血病的长期疗效分析[J]. 中国实验血液学杂志, 2020, 28(4): 1075-1080. DOI: 10.19746/j.cnki.issn1009-2137.2020.04.001.
4 Heikamp EB, Pui CH. Next-generation evaluation and treatment of pediatric acute lymphoblastic leukemia[J]. J Pediatr, 2018, 203: 14-24.e2. PMID: 30213460. PMCID: PMC6261438. DOI: 10.1016/j.jpeds.2018.07.039.
5 Arai N, Homma M, Abe M, et al. Impact of CD123 expression, analyzed by immunohistochemistry, on clinical outcomes in patients with acute myeloid leukemia[J]. Int J Hematol, 2019, 109(5): 539-544. PMID: 30847774. DOI: 10.1007/s12185-019-02616-y.
6 Angelova E, Audette C, Kovtun Y, et al. CD123 expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia[J]. Haematologica, 2019, 104(4): 749-755. PMID: 30361418. PMCID: PMC6442980. DOI: 10.3324/haematol.2018.205252.
7 Aref S, El Agdar M, Khaled N, et al. Clinical impact of CD25/CD123 coexpression in adult B-cell acute lymphoblastic leukemia patients[J]. Adv Hematol, 2020, 2020: 9545717. PMID: 32518561. PMCID: PMC7256740. DOI: 10.1155/2020/9545717.
8 Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia[J]. Blood, 2016, 127(20): 2391-2405. PMID: 27069254. DOI: 10.1182/blood-2016-03-643544.
9 尹润秀. CCLG-ALL2018方案儿童HR-ALL的临床特点及生存分析[D]. 昆明: 昆明医科大学, 2023.
10 岳文勤, 唐古生, 柳敏, 等. CD123在急性髓系白血病患者骨髓异常细胞群中的表达及预后价值[J]. 中华血液学杂志, 2017, 38(10): 876-882. DOI: 10.3760/cma.j.issn.0253-2727.2017.10.010.
11 Sun W, Malvar J, Sposto R, et al. Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study[J]. Leukemia, 2018, 32(11): 2316-2325. PMID: 29728694. PMCID: PMC6224404. DOI: 10.1038/s41375-018-0094-0.
12 Kandeel EZ, Madney Y, Eldin DN, et al. Overexpression of CD200 and CD123 is a major influential factor in the clinical course of pediatric acute myeloid leukemia[J]. Exp Mol Pathol, 2021, 118: 104597. PMID: 33358743. DOI: 10.1016/j.yexmp.2020.104597.
13 Das N, Gupta R, Gupta SK, et al. A real-world perspective of CD123 expression in acute leukemia as promising biomarker to predict treatment outcome in B-ALL and AML[J]. Clin Lymphoma Myeloma Leuk, 2020, 20(10): e673-e684. PMID: 32561191. DOI: 10.1016/j.clml.2020.05.004.
14 Li Z, Chu X, Gao L, et al. High expression of interleukin-3 receptor alpha chain (CD123) predicts favorable outcome in pediatric B-cell acute lymphoblastic leukemia lacking prognosis-defining genomic aberrations[J]. Front Oncol, 2021, 11: 614420. PMID: 33796456. PMCID: PMC8008053. DOI: 10.3389/fonc.2021.614420.
15 兰洋, 陈晓娟, 邹尧, 等. CCLG-ALL2008方案治疗10岁以上儿童及青少年急性淋巴细胞白血病的疗效分析[J]. 中国当代儿科杂志, 2019, 21(5): 405-410. PMID: 31104652. PMCID: PMC7389417. DOI: 10.7499/j.issn.1008-8830.2019.05.001.
16 Lamble AJ, Eidenschink Brodersen L, Alonzo TA, et al. CD123 expression is associated with high-risk disease characteristics in childhood acute myeloid leukemia: a report from the Children's Oncology Group[J]. J Clin Oncol, 2022, 40(3): 252-261. PMID: 34855461. PMCID: PMC8769096. DOI: 10.1200/JCO.21.01595.
17 蔡春霞, 郑湧智, 李健, 等. 高超二倍体核型儿童急性淋巴细胞白血病的临床特征及预后——福建省多中心回顾性研究[J]. 中国当代儿科杂志, 2023, 25(1): 38-45. PMID: 36655662. PMCID: PMC9893819. DOI: 10.7499/j.issn.1008-8830.2208126.
18 Bras AE, de Haas V, van Stigt A, et al. CD123 expression levels in 846 acute leukemia patients based on standardized immunophenotyping[J]. Cytometry B Clin Cytom, 2019, 96(2): 134-142. PMID: 30450744. PMCID: PMC6587863. DOI: 10.1002/cyto.b.21745.
19 Djokic M, Bj?rklund E, Blennow E, et al. Overexpression of CD123 correlates with the hyperdiploid genotype in acute lymphoblastic leukemia[J]. Haematologica, 2009, 94(7): 1016-1019. PMID: 19454491. PMCID: PMC2704314. DOI: 10.3324/haematol.2008.000299.
20 郑莹. CD123在儿童B系急性淋巴细胞性白血病中的表达与抗人CD123单克隆抗体的制备[D]. 苏州: 苏州大学, 2015.
21 李芝帆, 王君兰, 张格, 等. ALL患儿CCCG-ALL 2015方案化疗后早期微小残留病与预后的关系[J]. 解放军医药杂志, 2022, 34(10): 22-26. DOI: 10.3969/j.issn.2095-140X.2022.10.006.